Weight Loss Tips
Paying for Weight Loss Treatment in Instalments
A single large upfront cost is a genuine barrier for many people considering weight loss treatment. Here is how instalme...
Most people ask this expecting an answer in months. The honest answer is longer than that, and for many people it does not have an end point at all.
That is uncomfortable, particularly in a market where these drugs are expensive and unreliable to obtain. But planning around a realistic answer produces better outcomes than planning around a hopeful one.
What the trials actually measured
STEP 1, published in the New England Journal of Medicine, measured its 14.9 percent average weight reduction at 68 weeks.
SURMOUNT-1, also in the New England Journal of Medicine, measured 20.9 percent at the top tirzepatide dose at 72 weeks.
SCALE measured 8.4 kg on liraglutide at 56 weeks.
SEQUEL measured Qsymia's 10.5 percent at 108 weeks.
None of those is a three-month result. They describe continuous, uninterrupted treatment for well over a year.
Anyone budgeting for two or three months is planning for something the evidence does not describe.
The phases
Thinking in phases is more useful than a single duration.
Escalation, roughly weeks 1 to 16 to 20. Dose builds gradually. Side effects concentrate here. Weight loss begins but is not at full rate. This phase exists for tolerance, not results.
Active loss, roughly months 4 to 12 to 18. Full dose, steepest weight reduction. This is where the trial figures accumulate.
Plateau. Weight loss slows and stops as the body reaches a new equilibrium. This is expected rather than failure, and it typically occurs somewhere in the second year.
Maintenance. Continuing treatment to hold the result. This phase has no defined end.
Most people asking about duration are thinking about the first two phases. The fourth is where the difficulty lies.
Why stopping brings weight back
The mechanisms are physiological rather than a lack of resolve.
Appetite signalling returns to baseline when the drug is removed. The body defends its previous weight through raised ghrelin and lowered leptin. Resting energy expenditure is lower in a lighter body, and often lower than size alone predicts. Any lean tissue lost during the deficit compounds that.
The STEP 1 extension study found participants regained roughly two thirds of lost weight within about a year of stopping, with cardiometabolic improvements largely reverting.
That is why the framing "how long is the course" is slightly wrong. These medications manage a chronic condition while taken, in the same way blood pressure medication does.
The Pakistani reality
Indefinite treatment is not realistic for most households here.
Imported GLP-1 injections run Rs 20,000 to Rs 50,000 monthly, plus consultation and cold-chain costs, with no registration and frequent supply interruption. Sustaining that for years is beyond most budgets, and supply breaks would interrupt it even if the money held.
Pretending otherwise serves nobody. The useful question becomes: if treatment will end, what determines how much of the result survives?
What survives, and what does not
Three things carry forward after treatment stops.
Muscle. This is the highest-value asset. Muscle preserves resting energy expenditure, which is what makes maintenance possible. Adequate protein at 1.2 to 1.6 grams per kilogram daily plus resistance training during the loss phase determines how much you keep.
Habits. The appetite suppression period is a window where eating patterns can be changed with far less effort than usual. Someone who uses that window to establish portion sizes, meal composition and routine has something to fall back on. Someone who eats the same way and simply eats less does not.
Metabolic improvements, partially. Blood pressure, blood sugar and liver fat improvements track weight, so they revert with regain. But some vascular and metabolic benefit from a period at lower weight may persist.
What does not carry forward is appetite suppression itself. That ends when the drug does.
Planning a finite course
If you know treatment will be time-limited, structure it deliberately.
Decide the duration at the start, rather than continuing until money runs out.
Front-load habit building. Do not wait until month ten to think about what happens afterwards.
Prioritise protein and resistance training from week one, not as an afterthought.
Lose weight at a moderate pace. Aggressive rapid loss costs more lean tissue, which makes maintenance harder.
Plan the taper and the maintenance phase before you reach it. The end of treatment is the highest-risk period and deserves as much thought as the start.
Set a realistic target. Reaching a maintainable weight beats reaching a lower one you cannot hold.
The maintenance research
There is emerging evidence on stepping down rather than stopping outright.
The ATTAIN-MAINTAIN trial tested whether people who had lost weight on injectable Wegovy or Zepbound could switch to oral orforglipron and hold the result. It met its primary and all key secondary endpoints at 52 weeks.
That points toward a future where a stronger agent does the initial work and a simpler, cheaper one maintains. Neither drug is available in Pakistan, but the principle is relevant.
Where a structured programme fits
If sustainability rather than peak effect is the binding constraint, the calculation changes.
The METASLIM™ 8-week program is a defined structure with dietary guidance and physician review, delivered as physician-reviewed sublingual drops. It is not a pharmaceutical GLP-1 receptor agonist and does not produce STEP 1 or SURMOUNT-1 results.
Its relevance to this article is the framing. A programme with dietary guidance built in is designed around building the pattern that survives it, which is the variable that actually determines long-term outcome when indefinite treatment is not an option.
Our page on what the programme involves week by week covers the structure, and rebound weight gain after stopping covers what happens afterwards in detail.
The summary
Trial results describe 56 to 72 weeks of continuous treatment, not a few months.
Treatment runs through escalation, active loss, plateau and maintenance, and maintenance has no defined end.
Roughly two thirds of lost weight returned within a year of stopping in the STEP 1 extension.
For most households in Pakistan, indefinite treatment is not affordable, which makes planning a finite course the realistic approach.
Muscle and habits are what carry forward. Appetite suppression does not.
Decide the duration at the start, build habits from week one, and plan the maintenance phase before you reach it.
Review the full program details if you are planning a finite course.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.